Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed.

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

This case of drug-induced AGEP in pregnancy, the first described to the best of our knowledge, demonstrates the complex immune interplay between cytokines and effector cells in this pustular acute ...

Spesolimab showed rapid and meaningful effectiveness in treating flares of generalized pustular psoriasis (GPP) in clinical practice, supporting its use as a standard of care and aligning with results ...

A new study found that 57.6% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin clearance at week 20. Bio-naive status and lower comorbidity ...

Patanjali Ayurved's research, published in the Journal of Inflammation Research, reveals promising results for their Ayurvedic treatment of psoriasis using Psorogrit tablets and Divya Taila.

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

Clobazam was the most effective therapeutic intervention at a dose of 1mg/kg/day, achieving a 50% reduction in drop seizures. Among the considered first line options for patients with Lennox-Gastaut ...

Shiny white structures, atypical networks, and asymmetry of globules are among the dermoscopic findings that may help clinicians differentiate low-grade dysplastic nevi from other lesions. Early ...